Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole in Acute Schizophrenia (BEACON)
NCT01393613Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in schizophrenia (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Jul 2011; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01393613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01393613.